HIV-1-INFECTION

This early-stage trial tested a new HIV vaccine called INO-6160 in 20 healthy adults without HIV. The vaccine uses synthetic DNA to teach the body to recognize HIV and includes an immune booster (Interleukin-12). Some participants also received a booster shot with a different HIV…

This early-phase study tested a new gene therapy approach in 2 HIV patients who also had high-risk lymphoma. The therapy involved taking the patients' own blood stem cells and immune cells, adding a protective gene (Cal-1) to make them resistant to HIV, and then giving them back …

This study tested whether a stronger tuberculosis (TB) treatment could reduce deaths in people with HIV who have very low immune cell counts (CD4 ≤ 100). Over 1,300 hospitalized adults and teens received either an intensified drug regimen (with extra rifampicin, isoniazid, predni…

This study tested two different once-daily HIV medication combinations in 101 people recently infected with HIV-1. The goal was to see which combo better reduced the amount of HIV hiding in immune cells (the viral reservoir) after 48 weeks. Both treatments are designed to control…

This study tested a mix of plant extracts and vitamin C in 60 HIV/AIDS patients to see if it could protect and increase key immune cells (CD4+ and B lymphocytes). The goal was to slow HIV's damage to the immune system. The treatment is meant to be taken alongside standard HIV med…

This study tested whether adults with well-controlled HIV could safely switch from a daily pill to a once-weekly combination of two experimental drugs (islatravir and MK-8507). 161 participants who had been virally suppressed for at least 6 months took part. The main goal was to …

This study tested a switch to a two-drug HIV treatment (raltegravir and etravirine) in 170 adults aged 45 and older who already had their virus under control. After 96 weeks, nearly all participants (99%) still had undetectable virus levels. The simpler regimen may reduce side ef…

This study tested whether Trogarzo, an HIV medication, can be given safely as a quick IV push (over 30 seconds) or as a muscle injection instead of a longer IV drip. It involved 43 people with stable HIV who were already taking Trogarzo, plus some healthy volunteers. The goal was…

This study followed 27 HIV-positive people with kidney failure who received a kidney transplant. Researchers wanted to see how many had organ rejection within 6 months while taking a three-drug HIV regimen including raltegravir. The goal was to learn how to better manage transpla…

This study looked at 33 adults with well-controlled HIV who switched from a monthly injectable treatment (CAB+RPV) to a daily oral pill (B/F/TAF). The main goal was to check for serious side effects over 12 weeks. Researchers found that the switch was safe, with no major drug-rel…

This study tested an experimental drug called PRO 140 in 6 adults with HIV whose current medications were no longer controlling the virus. The goal was to see if adding PRO 140 could lower the amount of HIV in their blood. The trial lasted 25 weeks and combined PRO 140 with other…

This study looked back at medical records of 800 adults with HIV to compare two drug combinations: a two-drug regimen (DTG/3TC) and a three-drug regimen (BIC/F/TAF). The goal was to see how well each kept the virus under control over 48 weeks. The study took place in multiple cli…

This early-stage study tested a new experimental drug, GS-3242, in 27 people living with HIV-1. The goal was to see if the drug is safe and can lower the amount of virus in the blood. Participants had not taken HIV medicines for at least 12 weeks before joining. The study measure…

This study tested the safety of two lab-made HIV antibodies (VRC07-523LS and CAP256V2LS) followed by an immune-boosting drug (vesatolimod) in 20 women with HIV who were already on standard antiretroviral therapy (ART). The goal was to see if this combination could help control th…

This study tested a cell phone app called START to help men who have HIV and use stimulants like methamphetamine stick to their HIV medication. The goal was to see if the app could lower their viral load and reduce stimulant use. The study involved 286 men and compared the app to…

This study tested a new experimental drug, STP0404, in 25 adults with HIV who had never taken HIV medications before. The goal was to see how well the drug lowers the amount of virus in the blood and to check for side effects over a 10-day period. The results will help decide if …

This study looked at a new HIV medication combination (dolutegravir plus two NRTIs) in 19 people with HIV who had received a solid organ transplant (kidney, liver, or heart). The goal was to see if the drug combo is safe and effective, and how it interacts with the anti-rejection…

This study tested whether taking fecal transplants (FMT) in capsules could reduce gut inflammation in people with HIV who are on antiretroviral therapy (ART) but have a low CD4/CD8 ratio. Twenty participants were split into two groups: one received FMT capsules and the other rece…

This study tested a new once-daily combination pill (doravirine/islatravir) in 599 adults newly diagnosed with HIV who had never taken HIV medication. The goal was to see if the new pill could control the virus as well as or better than a standard three-drug regimen. Results show…

This study tested a combination of two lab-made antibodies (TMB-365 and TMB-380) in 51 adults with HIV whose virus was already well-controlled by daily oral medication. The goal was to see if these antibodies, given as intravenous infusions every 8 weeks, could safely keep the vi…

This study tested a program to help people over 50 living with HIV build resilience and better handle daily stress. 106 participants from an HIV clinic took part. The program used daily text messages to track how they coped with stressors and their emotional reactions. The goal w…

This study looked at how much HIV medication passes from mother to baby through breastmilk. Sixteen HIV-positive mothers who chose to breastfeed provided blood and breastmilk samples at 1, 3, and 6 months after giving birth. Researchers measured drug levels to calculate how much …

This study looked at how moderate drinking affects inflammation and brain health in people with HIV. Researchers gave controlled amounts of alcohol to 76 healthy volunteers and people with HIV, then used blood tests and MRI scans to measure immune and brain changes. The goal was …

This study looked at 80 HIV patients on long-term treatment to understand why their gut immune barrier doesn't fully heal. Even when the virus is controlled, a 'leaky gut' can cause harmful inflammation. Researchers measured specific immune cells in the blood and gut to find out …

This study tested whether the BCG vaccine, typically used for tuberculosis, could reduce the amount of HIV hiding in the body (the latent reservoir) in people already on HIV medication. 60 adults with well-controlled HIV took part. The main goal was to measure changes in the size…

This study looked at 20 men with HIV who were stable on a common drug combination. Researchers measured how much of the drugs reached key body tissues like lymph nodes, fat, rectum, and sperm. The goal was to understand where the virus might hide despite treatment, which could he…

This study looked at how a single dose of methamphetamine affects HIV activity in 14 people with HIV who were on effective treatment and had no history of meth use. Researchers measured changes in HIV production and inflammation over 4 hours. The goal was to understand how meth m…